Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Apr

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D Mutated NSCLC

Nonoperative Management of Mismatch Repair Deficient Tumors

Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies

Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer

Addition of Neoadjuvant Adjuvant Pembrolizumab Significantly Improves Outcomes in Locally Advanced HNSCC